CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum
16 Maio 2023 - 8:00AM
Business Wire
CareDx Symposium Addresses Barriers in Access
to Transplantation
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine
company focused on the discovery, development, and
commercialization of clinically differentiated, high-value
healthcare solutions for transplant patients and caregivers – today
announced that it will showcase its digital health portfolio and
host a symposium which addresses barriers in access to
transplantation at the 31st Annual UNOS Transplant Management Forum
(TMF) taking place May 16-18 in Denver, Colorado. CareDx is the
leading Diamond level sponsor of this year’s UNOS TMF.
"Improving the transplant journey is at the heart of everything
we do, and we are thrilled to showcase how our investment in
cutting-edge digital health solutions is making a meaningful impact
across the board with ever-increasing adoption,” said Kashif
Rathore, Chief of Patient and Digital Solutions at CareDx. “CareDx
is proud to participate in this important yearly forum to
demonstrate how our connected set of transplant management
solutions enables more cohesive care in the complex transplant
ecosystem.”
CareDx will be hosting an interactive symposium, “Increasing
Access to Transplant While Managing the Chaos.” This session, led
by distinguished specialist Koren Axelrod, Director of Quality at
CareDx, will be held May 16 from 12:45pm to 1:30pm MDT, covering
the following topics:
- Identifying external and internal barriers limiting transplant
access to patients
- Recognizing the impact of increased transplant access on
centers
- Digital solutions and partnership development tools (with
referring providers, patients and others) to manage this
impact
CareDx will be on hand to display its industry-leading suite of
innovative transplant management solutions, enabling more cohesive
care and efficiency across the transplant pre- and post-transplant
journey.
"By leveraging the power of CareDx’s integrated digital health
solutions, we're transforming the way we deliver care, streamlining
operational workflows, improving quality metrics, and providing
greater access to healthcare services,” said Emilie Burgess, LMSW,
Director, Solid Organ Transplant, Medical City Dallas, Medical City
Children’s Hospital. “Furthermore, with these tools, we're also
empowering patients to have greater control of their experience,
while also giving them a more efficient, effective, and
personalized healthcare experience."
CareDx’s suite of digital health solutions include the AlloCare®
mobile health app which is fully integrated with AlloHome® remote
patient monitoring and TxAccess® to help track biometrics and
better manage the transplant waitlist process, medication
adherence, and ongoing education. These digital solutions along
with MedActionPlan® PRO streamline communications, facilitate
earlier interventions, and empower patients to take greater control
of their care. The Transplant Pharmacy provides individualized
transplant pharmacy services to help facilitate medication
adherence and education, and Ottr® and TransChart® help centers
manage transplant workflows to achieve clinical efficiencies, and
through the use of XynQAPI® improvements in quality of care and
patient outcomes. CareDx also offers HLA Data Systems mTilda, a
leading lab information management software (LIMS) for human
leukocyte antigen (HLA) laboratories.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the potential
benefits and results that may be achieved with CareDx’s digital
health portfolio, as well as CareDx’s leading participation at the
31st annual UNOS Transplant Management Forum (the “Participation”).
These forward-looking statements are based upon information that is
currently available to CareDx and its current expectations, speak
only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including risks that CareDx does not realize
the expected benefits of its digital health portfolio or
Participation; general economic and market factors; and other risks
discussed in CareDx’s filings with the SEC, including the Annual
Report on Form 10-K for the fiscal year ended December 31, 2022
filed by CareDx with the SEC on February 27, 2023, the quarterly
report on Form 10-Q for the quarter ended March 31, 2023 filed by
CareDx with the SEC on May 10, 2023, and other reports that CareDx
has filed with the SEC. Any of these may cause CareDx’s actual
results, performance, or achievements to differ materially and
adversely from those anticipated or implied by CareDx’s
forward-looking statements. CareDx expressly disclaims any
obligation, except as required by law, or undertaking to update or
revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230516005504/en/
CareDx, Inc.
Media Relations Anna Czene 818-731-2203 aczene@caredx.com
Investor Relations Greg Chodaczek Investor@caredx.com
CareDx (NASDAQ:CDNA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
CareDx (NASDAQ:CDNA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024